These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 8198578)

  • 1. Identification of a new class of ETA selective endothelin antagonists by pharmacophore directed screening.
    Chan MF; Okun I; Stavros FL; Hwang E; Wolff ME; Balaji VN
    Biochem Biophys Res Commun; 1994 May; 201(1):228-34. PubMed ID: 8198578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of two novel mixed ETA/ETB receptor antagonists, BQ-928 and 238, in the carotid and pulmonary arteries and the perfused kidney of the rabbit.
    Maurice MC; Gratton JP; D'Orléans-Juste P
    Br J Pharmacol; 1997 Jan; 120(2):319-25. PubMed ID: 9117126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional and binding characterization of endothelin receptors in human bronchus: evidence for a novel endothelin B receptor subtype?
    Hay DW; Luttmann MA; Pullen MA; Nambi P
    J Pharmacol Exp Ther; 1998 Feb; 284(2):669-77. PubMed ID: 9454813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-mediated effects of endothelin on the L-type Ca++ current in ventricular cardiomyocytes.
    Kelso EJ; Spiers JP; McDermott BJ; Scholfield CN; Silke B
    J Pharmacol Exp Ther; 1998 Aug; 286(2):662-9. PubMed ID: 9694918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective endothelin A receptor antagonists. 3. Discovery and structure-activity relationships of a series of 4-phenoxybutanoic acid derivatives.
    Astles PC; Brealey C; Brown TJ; Facchini V; Handscombe C; Harris NV; McCarthy C; McLay IM; Porter B; Roach AG; Sargent C; Smith C; Walsh RJ
    J Med Chem; 1998 Jul; 41(15):2732-44. PubMed ID: 9667964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of peptide and nonpeptide antagonists in human kidney.
    Kuc RE; Karet FE; Davenport AP
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S373-5. PubMed ID: 8587419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
    Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
    J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.
    Ohlstein EH; Nambi P; Hay DW; Gellai M; Brooks DP; Luengo J; Xiang JN; Elliott JD
    J Pharmacol Exp Ther; 1998 Aug; 286(2):650-6. PubMed ID: 9694916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships of a novel series of orally active nonpeptide ETA and ETA/B endothelin receptor-selective antagonists.
    Doherty AM; Patt WC; Repine J; Edmunds JJ; Berryman KA; Reisdorph BR; Walker DM; Haleen SJ; Keiser JA; Flynn MA
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S358-61. PubMed ID: 8587414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors.
    Nambi P; Pullen M; Wu HL; Lee D; Saunders D; Heys R; Aiyar N; Leber J; Elliott J; Brooks D; Ohlstein E; Ruffolo R
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1567-71. PubMed ID: 8667224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors.
    Masuda Y; Sugo T; Kikuchi T; Kawata A; Satoh M; Fujisawa Y; Itoh Y; Wakimasu M; Ohtaki T
    J Pharmacol Exp Ther; 1996 Nov; 279(2):675-85. PubMed ID: 8930171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional variations in ETA/ETB binding sites in human coronary vasculature.
    Dashwood MR; Timm M; Kaski JC
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S351-4. PubMed ID: 8587412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
    Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis of the endothelin type A receptor (ETA): interactions and model of selective ETA antagonist BMS-182874 with putative ETA receptor binding cavity.
    Webb ML; Patel PS; Rose PM; Liu EC; Stein PD; Barrish J; Lach DA; Stouch T; Fisher SM; Hadjilambris O; Lee H; Skwish S; Dickinson KE; Krystek SR
    Biochemistry; 1996 Feb; 35(8):2548-56. PubMed ID: 8611558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of endothelin and ETB receptors in the megakaryoblastic MEG-01 cell line.
    Hamroun D; Mathieu MN; Clain E; Germani E; Laliberté MF; Laliberté F; Chevillard C
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S156-8. PubMed ID: 8587350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and selective non-benzodioxole-containing endothelin-A receptor antagonists.
    Tasker AS; Sorensen BK; Jae HS; Winn M; von Geldern TW; Dixon DB; Chiou WJ; Dayton BD; Calzadila S; Hernandez L; Marsh KC; WuWong JR; Opgenorth TJ
    J Med Chem; 1997 Jan; 40(3):322-30. PubMed ID: 9022798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists.
    Riechers H; Albrecht HP; Amberg W; Baumann E; Bernard H; Böhm HJ; Klinge D; Kling A; Müller S; Raschack M; Unger L; Walker N; Wernet W
    J Med Chem; 1996 May; 39(11):2123-8. PubMed ID: 8667356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Endothelin receptors in benign human tumours of uterine muscle].
    Breuiller-Fouché M; Honoré JC; Robert B; Fournier T; Vacher-Lavenu MC; Chapron C; Dubuisson JB; Ferré F
    Bull Cancer; 1999 Sep; 86(9):773-8. PubMed ID: 10519970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore modeling of dual angiotensin II and endothelin A receptor antagonists.
    Xue WZ; Lü W; Zhou ZM; Wang ZL
    Yao Xue Xue Bao; 2009 Sep; 44(9):1002-8. PubMed ID: 20055175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin receptor antagonists: status and learning 20 years on.
    Palmer MJ
    Prog Med Chem; 2009; 47():203-37. PubMed ID: 19328292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.